Global Pharmaceutical Contract Manufacturing Market Injectable Dose Formulations Will Likely Spur the Growth of CMOs

Like this? Share it with your network

Share

Global Pharmaceutical Contract Manufacturing Market Injectable Dose Formulations Will Likely Spur the Growth of CMOs

  • 2,486 views
Uploaded on

Cost benefits and pharmaceutical companies’ desire to focus on their core competencies has created an increasing need for outsourcing and spurred the global pharmaceutical contract manufacturing......

Cost benefits and pharmaceutical companies’ desire to focus on their core competencies has created an increasing need for outsourcing and spurred the global pharmaceutical contract manufacturing market. Expiring blockbuster drug patents will reduce manufacturing capacity utilization rates and boost outsourcing further.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Global Pharmaceutical Contract Manufacturing Market, finds the market earned revenue of $13.43 billion in 2012 and estimates this to reach $18.49 billion in 2017. This research explores solid dose, liquid and semi-solid dose, and injectable dose formulations.

For more information on this analysis, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
2,486
On Slideshare
2,486
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
76
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Global Pharmaceutical Contract Manufacturing Market Injectable Dose Formulations Will Likely Spur the Growth of CMOs NC04-52 August 2013
  • 2. 2NC04-52 Scope and Segmentation Geographic coverage Global: United States, Europe (Germany, United Kingdom, France, Italy, Spain, Scandinavia, and Benelux), and Rest of World (ROW) Study period 2009–2017 Base year 2012 Forecast period 2013–2017 Monetary unit US Dollars Conversion rate €1 = $1.31 Source: Frost & Sullivan
  • 3. 3NC04-52 Market Segmentation The pharmaceutical contract manufacturing market can be broadly divided into 3 main segments: solid dose formulations, liquid and semi-solid dose formulations, and injectable dose formulations. • Solid dose formulations comprise basic (tablets and capsules) and advanced (controlled-release), fast- dissolving, and soft-gel, which are multi-active pharmaceutical ingredient (API) oral finished dose formulations. • Liquid and semi-solid dose formulations include nasal, nebulized, ophthalmic, otic, and topical formulations, including sterile and non-sterile preparations. • Injectable dose formulations are sterile preparations, including small- and large-volume parenterals. Small-volume parenterals are of 2 types: cytotoxic and non-cytotoxic. Solid Dose Formulations Liquid and Semi-solid Dose Formulations Total Pharmaceutical Contract Manufacturing Market Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012 Injectable Dose Formulations Market Segmentation Source: Frost & Sullivan
  • 4. 4NC04-52 Segment Lifecycle Analysis Injectable Dose Formulations MaturityDevelopment Growth Decline Time SegmentValue Solid Dose Formulations Injectable dose formulations is the fastest growing segment, with a projected growth rate of 12.2% in 2012, which is higher than the overall pharmaceutical contract manufacturing market. Increased focus on cytotoxics, lyophilised prefilled syringes, and reformulation of existing products is expected to drive the remarkable success of injectables. The liquid and semi-solid dose formulations segment is declining because of storage and transportation issues, with the major target group being the paediatric population. Minimal R&D is also carried out in this segment. Solid dose formulations is the largest segment of the global pharmaceutical contract manufacturing market. Growth in this segment is primarily attributed to lower cost, ease of manufacturing, patient compliance, and the patent cliff. Note: Bubble size represents market size. Liquid and Semi-solid Dose Formulations Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012 Source: Frost & Sullivan
  • 5. 5NC04-52 Market Engineering Measurements Market Stage Growth Market Revenue $13.43 B (2012) Market Penetration Medium (2012) Market Nature Fragmented Market Size for Last Year of Study Period $18.49 B (2017) Base Year Market Growth Rate 5.9% Compound Annual Growth Rate 6.6% (CAGR, 2012 - 2017) Customer Price Sensitivity 9 (scale:1 [low] to 10 [High]) Degree of Technical Change 8 (scale:1 [low] to 10 [High]) For a tabular version click here. Market Concentration 23.0% Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Global, 2012 Market Overview (% of market share held by top 3 companies) Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan Stable IncreasingDecreasing
  • 6. 6NC04-52 Number of Competitors Nearly 450 (active market competitors in 2012) Number of Generic Manufacturers High (none, low, medium, high) Market Engineering Measurements (continued) Competitor Overview Number of Companies that Entered < 10 (2012) Additional Key Metrics Average Product Development Time 5–10 years Stable IncreasingDecreasing Industry Capacity Utilisation Rate 45.0% (2012) Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan
  • 7. 7NC04-52 CEO’s Perspective 2 The pharmaceutical contract manufacturing market is highly fragmented, and consolidation is required to improve profitability. 3 Thirty percent of existing participants could exit the market due to pricing pressure and low profit margins, mainly in the liquid and semi-solid dose formulations segment. 4 Capturing projects at the early life-cycle stage of products and a risk-sharing business model can help build long-term strategic relationships. 1 Lyophilisation and manufacturing of sterile products such as cytotoxics will likely be areas of growth potential, given the demand for oncology and high-potency drugs.
  • 8. 8NC04-52 Key Findings • In 2012, the global pharmaceutical contract manufacturing market generated $13.43 billion in revenue. The forecast shows a compound annual growth rate (CAGR) of 6.6% from 2012 to 2017. o The injectable dose formulations segment will likely be the primary growth driver for outsourcing throughout the forecast period. • In 2012, solid dose formulations was the largest segment, constituting 49.8% of the total pharmaceutical contract manufacturing market, and is projected to grow at a CAGR of 3.4% from 2012 to 2017. o Generics will likely be a key growth driver for the solid dose formulations segment; however, this segment will likely lose shares to the injectable dose formulations segment because of big pharma’s shift in focus from small molecules to large molecules. • Injectable dose formulations is the fastest growing segment and is projected to register a robust CAGR of 13% from 2012 to 2017. o Key growth drivers include increased pharmaceutical and biotechnological focus on complex disease areas, trends in disease control, growth in emerging markets, the pharmaceutical patent cliff (several blockbuster drugs losing patent protection), and reformulation of existing products. o The major growth contributor is expected to be cytotoxics as both cancer research and the development of new cancer therapies are driving growth in this area. Source: Frost & Sullivan
  • 9. 9NC04-52 • The liquid and semi-solid dose formulations segment is quite mature and expected to experience a relatively lower CAGR of 2.5% from 2012 to 2017. o Decreasing demand for liquid dose formulations is primarily attributed to transportation, storage, and packaging issues associated with these formulations as well as lower returns compared to injectable dose formulations manufacturing. o The sterile liquid and semi-solid dose preparations, particularly nasal ophthalmic dose formulations, are expected to experience strong growth; however, these preparations currently constitute a very small segment of the market. • Because of big pharma’s increased outsourcing, the pharmaceutical contract manufacturing market is expected to show consistent growth. CMOs are striving to provide greater value proposition for clients by engaging in the early life-cycle stage projects and establishing long-term relationships. o To improve their value proposition to manufacturers, many CMOs are focusing on pre-clinical development services and can transition from offering clinical services to offering commercial manufacturing to integrate throughout the value chain of clients. • Industry consolidation is on an increasing curve. The fragmented market nature will likely intensify pricing pressure and drive down CMO revenues. • Catalent Inc., Patheon Inc., and Aenova (with the acquisition of the Temmler group) are the top 3 market participants, constituting a combined share of 23% in the global pharmaceutical contract manufacturing market. Key Findings (continued) Source: Frost & Sullivan
  • 10. 10NC04-52 Defining CMO Trends in the Future Topic Present (2012) Future Outlook (2022) Key Areas Outsourced A majority of CMOs currently outsource development activities such as formulations, toxicity testing, fill and finish services, and product characterization activities. Outsourcing of crucial operations such as upstream and downstream processes is likely in the interest of time, cost, and efficiency. Capacity Utilisation The global industry capacity utilisation rate is nearly 45%. The global industry capacity utilisation rate is expected to increase 55 to 60% because of several blockbuster drugs coming out of patent, new product launches, and more plant shut downs. Role of Venture Capital (VC) Firms The lack of interest from VC firms to invest in CMO space is because of poor profitability and an unstable economic climate. VC investments may solidify when the economy gains more steam. CMOs in emerging markets could be potential targets for investments. Industry Consolidation Consolidation in the form of strategic partnerships between CMOs, pharmaceutical and biotech companies, drug delivery companies, and technology providers is on an increasing curve. There will be greater consolidation and emphasis on core dose formulations in the global CMO market. Thirty percent of current participants will likely exit over the next 10 years because of intense price competition and poor profit margins, particularly in liquid and semi- solid dose formulations. Favored Destinations for Outsourcing Currently, the United States and Europe are major markets for outsourcing of finished dose formulations and sterile preparations, while Asian CMOs are preferred destinations for APIs, intermediates, and generics. Given the immense cost benefits, Asian CMOs such as in India, China, and Singapore will likely emerge as favorable destinations, particularly for solid dose formulations. Business Model Several CMOs focus on manufacturing services as their core business segment. Adherence to an integrated end-to-end business model offers value- added services, thereby serving as a one-stop shop for customers. How will your company meet the future needs of the industry? Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and 2022 Source: Frost & Sullivan
  • 11. 11NC04-52 New Market Opportunities Unmet Needs • An integrated, end-to-end business model on a risk sharing basis with clients • Instilling new capabilities and anticipating capacity demand for careful outweighing of benefits and risks • Huge demand for next-generation biological therapies such as vaccines, anti-cancer therapies, gene therapies, specialized antibiotic treatments, and recombinant proteins Current Participant Strategies • Repositioning product/service offerings to enhance value proposition among clients and building long-term strategic partnerships on a risk-sharing basis • Acquiring new capabilities and capacity expansions by means of strategic partnerships to fulfill global demand • Increased focus on niche specialties such as aseptic manufacturing of injectable dose formulations to reap higher profit margins Source: Frost & Sullivan
  • 12. 12NC04-52 Key Companies to Watch Patheon Inc. • Patheon provides services to more than 300 clients, including the world’s 20 largest pharmaceutical companies, 9 of the 20 largest specialty pharmaceutical companies, and 10 of the 20 largest biotech companies. • Patheon has a strong track record in the solid dose formulations segment, with one of the highest number of solid dose drugs worldwide. • Patheon has one of the highest number of FDA new drug approvals compared to most other CMOs. Aenova • Aenova is one of the world’s largest full-service providers in the solid dose formulations segment, with cutting-edge technologies in the production of a wide range of tablets and capsules. • Aenova experienced a significant increase in market shares after acquiring the Temmler Group. • Aenova acquired new capabilities in products (liquid and semi-solid dose formulations) and services (manufacturing of clinical trial materials, logistics, distribution, and licensing). Baxter BioPharma Solutions • Baxter is well known for its proven expertise in parenteral dose manufacturing, with more than 1 billion sterile units manufactured per year. • Baxter was the first company to introduce premixed drugs in IV containers and the first company to package its drugs in IV containers. • Baxter has an established physician user base worldwide, providing valuable distribution channels to expedite new product launches combined with strong sales and marketing support services. For additional information on companies, click here. Source: Frost & Sullivan
  • 13. 13NC04-52 2 Given the highly fragmented market nature and intense competition, CMO providers will likely adopt a differentiation strategy to reposition themselves among clients. 3 Investments and capacity expansions in the injectable dose formulations segment, particularly cytotoxics manufacturing, are expected as they are anticipated to be the most significant sources of revenue for the pharmaceutical contract manufacturing industry. 1 Consolidation and an emphasis on core dose formulations will likely continue in the pharmaceutical contract manufacturing market. Thirty percent of the current market participants will likely exit over the next 10 years. Executive Summary—3 Big Predictions Source: Frost & Sullivan
  • 14. 14NC04-52 Contents Section Slide Number Executive Summary 25 • Scope and Segmentation 26 • Market Segmentation 27 • Key Questions This Study Will Answer 28 • Market Engineering Measurements 29 • CEO’s Perspective 31 • Key Findings 32 • Key Companies to Watch 34 • Executive Summary—3 Big Predictions 35 • The Last Word—Discussion 36 Market Overview 39 • Market Segmentation 40 • Segmentation by Manufacturing Process 41 • Segmentation by Patent Exclusivity Status 42 • Global Market Perspective 43 • Defining CMO Trends in the Future 44
  • 15. 15NC04-52 Contents (continued) Section Slide Number Competitive Playbook 45 • New Market Opportunities 46 • Key Merger, Acquisition and Partnership Assessment 48 Drivers, Restraints, and Trends—Total Pharmaceutical Contract Manufacturing Market 51 • Market Drivers 52 • Market Restraints 53 • Market Impact of Key Drivers and Restraints 54 Forecasts and Trends—Total Pharmaceutical Contract Manufacturing Market 55 • Market Engineering Measurements 56 • Forecast Assumptions 58 • Revenue Forecast 59 • Revenue Forecast Discussion 60 • Percent Revenue Forecast by Region 63 • Revenue Forecast by Region 64 • Key Market Trends 65
  • 16. 16NC04-52 Contents (continued) Section Slide Number • Key Technology Trends 72 • Market Impact of Key Trends 76 • Venture Capital Trends in CMO 77 • Segment Lifecycle Analysis 78 End-User Analysis/Demand Analysis—Total Pharmaceutical Contract Manufacturing Market 79 • End-user Survey Objectives 80 • End-user Survey Methodology 81 • Outsourcing Trend Analysis by Company Type 82 • Number of CMOs Companies Work With and by Company Type 83 • End-user Classification Based on CMO Use 84 • End-user Breakdown by Company Type 85 • Criteria for CMO Selection 86 • Top 5 Factors for CMO Selection 87 • Top 5 Factors for CMO Selection Discussion 88 • Stated Versus Unstated Importance of Selection Factors 89
  • 17. 17NC04-52 Contents (continued) Section Slide Number • Stated Versus Unstated Importance of Selection Factors Discussion 90 • Extent of Outsourcing to CMOs by Service Areas 91 • Analysis of Outsourcing Budget Based on Product Revenue 92 • Outsourcing of Pharmaceutical Manufacturing Demand Forecast 93 • Industry Capacity Utilisation Forecast 94 • Industry Capacity Utilisation Forecast Discussion 95 Market Share and Competitive Analysis—Total Pharmaceutical Contract Manufacturing Market 96 • Market Share 97 • Market Share Analysis 98 • CMO Breakdown by Finished Dose Segments 100 Solid Dose Formulations Segment Breakdown 130 • Solid Dose Formulations Segment Key Findings 131 • Market Engineering Measurements 132 • Revenue Forecast 133 • Revenue Forecast Discussion 134
  • 18. 18NC04-52 Contents (continued) Section Slide Number Liquid and Semi-solid Dose Formulations Segment Breakdown 136 • Liquid and Semi-solid Dose Formulations Segment Key Findings 137 • Market Engineering Measurements 139 • Revenue Forecast 139 • Revenue Forecast Discussion 140 Injectable Dose Formulations Segment Breakdown 141 • Injectable Dose Formulations Segment Key Findings 142 • Market Engineering Measurements 143 • Revenue Forecast 144 • Revenue Forecast Discussion 145 United States Breakdown 147 • US Pharmaceutical Contract Manufacturing Market—Market Engineering Measurements 148 • US Pharmaceutical Contract Manufacturing Market Revenue Forecast 149 • US Pharmaceutical Contract Manufacturing Market Revenue Forecast Discussion 150 • Solid Dose Formulations Segment Revenue Forecast 151
  • 19. 19NC04-52 Contents (continued) Section Slide Number • Solid Dose Formulations Segment Revenue Forecast Discussion 152 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 153 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 154 • Injectable Dose Formulations Segment Revenue Forecast 155 • Injectable Dose Formulations Segment Revenue Forecast Discussion 156 • Pricing Analysis 157 • Market Analysis 158 • PESTLE Analysis 159 Europe Breakdown 160 • European Pharmaceutical Contract Manufacturing Market—Market Engineering Measurements 161 • European Pharmaceutical Contract Manufacturing Market Revenue Forecast 162 • European Pharmaceutical Contract Manufacturing Market Revenue Forecast Discussion 163 • Solid Dose Formulations Segment Revenue Forecast 164 • Solid Dose Formulations Segment Revenue Forecast Discussion 165
  • 20. 20NC04-52 Contents (continued) Section Slide Number • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 166 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 167 • Injectable Dose Formulations Segment Revenue Forecast 168 • Injectable Dose Formulations Segment Revenue Forecast Discussion 169 • Pricing Analysis 170 • Market Analysis 171 • PESTLE Analysis 172 United Kingdom Breakdown 173 • Solid Dose Formulations Segment Revenue Forecast 174 • Solid Dose Formulations Segment Revenue Forecast Discussion 175 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 176 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 177 • Injectable Dose Formulations Segment Revenue Forecast 178 • Injectable Dose Formulations Segment Revenue Forecast Discussion 179 Germany Breakdown 180 • Solid Dose Formulations Segment Revenue Forecast 181
  • 21. 21NC04-52 Contents (continued) Section Slide Number • Solid Dose Formulations Segment Revenue Forecast Discussion 182 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 183 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 184 • Injectable Dose Formulations Segment Revenue Forecast 185 • Injectable Dose Formulations Segment Revenue Forecast Discussion 186 France Breakdown 187 • Solid Dose Formulations Segment Revenue Forecast 188 • Solid Dose Formulations Segment Revenue Forecast Discussion 189 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 190 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 191 • Injectable Dose Formulations Segment Revenue Forecast 192 • Injectable Dose Formulations Segment Revenue Forecast Discussion 193 Italy Breakdown 194 • Solid Dose Formulations Segment Revenue Forecast 195 • Solid Dose Formulations Segment Revenue Forecast Discussion 196
  • 22. 22NC04-52 Contents (continued) Section Slide Number • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 197 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 198 • Injectable Dose Formulations Segment Revenue Forecast 199 • Injectable Dose Formulations Segment Revenue Forecast Discussion 200 Spain Breakdown 201 • Solid Dose Formulations Segment Revenue Forecast 202 • Solid Dose Formulations Segment Revenue Forecast Discussion 203 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 204 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 205 • Injectable Dose Formulations Segment Revenue Forecast 206 • Injectable Dose Formulations Segment Revenue Forecast Discussion 207 Scandinavia Breakdown 208 • Solid Dose Formulations Segment Revenue Forecast 209 • Solid Dose Formulations Segment Revenue Forecast Discussion 210 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 211 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 212
  • 23. 23NC04-52 Contents (continued) Section Slide Number • Injectable Dose Formulations Segment Revenue Forecast 213 • Injectable Dose Formulations Segment Revenue Forecast Discussion 214 Benelux Breakdown 215 • Solid Dose Formulations Segment Revenue Forecast 216 • Solid Dose Formulations Segment Revenue Forecast Discussion 217 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 218 • Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 219 • Injectable Dose Formulations Segment Revenue Forecast 220 • Injectable Dose Formulations Segment Revenue Forecast Discussion 221 Key Companies to Watch 222 • Key Companies to Watch 223 • Catalent 224 • Patheon 227 • Aenova 230 • Famar 233 • Fareva 236
  • 24. 24NC04-52 Contents (continued) Section Slide Number • Haupt Pharma AG 239 • Recipharm AB 242 • DPT Laboratories 245 • Aesica 248 • Baxter BioPharma Solutions 251 • Vetter Pharma 254 • Hospira One 2 One 257 • NextPharma Technologies 260 The Last Word 263 • The Last Word—Three Big Predictions 264 • The Last Word—Discussion 265 • Legal Disclaimer 268 Appendix 269 • Market Background 270 • Important Market Metrics 271 • Market Landscape and Pricing 272
  • 25. 25NC04-52 Contents (continued) Section Slide Number • Drivers Explained 273 • Restraints Explained 278 • US Patent Expiration Timetable 282 • Europe Patent Expiration Timetable 284 • Decision Support Database—Total Healthcare Expenditure 291 • Decision Support Database—Public Healthcare Expenditure 293 • Decision Support Database—Private Healthcare Expenditure 295 • Additional Sources of Information on Contract Outsourcing Services 297 • List of Other Key Companies Included in this Research Service 298 • Market Engineering Methodology 299 • Learn More—Next Steps 300
  • 26. 26NC04-52 List of Exhibits Section Slide Number Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012 27 Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Global, 2012 29 Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by Segments, Global, 2012 40 Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by Manufacturing Process, Global, 2012 41 Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by Patent Exclusivity Status, Global, 2012 42 Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Breakdown by Geographic Region, Global, 2012 43 Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and 2022 44 Total Pharmaceutical Contract Manufacturing Market: Game-changing Strategies, Global, 2012 47 Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2010–2012 50 Total Pharmaceutical Contract Manufacturing Market: Key Market Drivers, Global, 2013– 2017 52
  • 27. 27NC04-52 List of Exhibits (continued) Section Slide Number Total Pharmaceutical Contract Manufacturing Market: Key Market Restraints, Global, 2013–2017 53 Total Pharmaceutical Contract Manufacturing Market: Impact of Key Drivers and Restraints, Global, 2012 54 Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Global, 2012 57 Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Global, 2009–2017 59 Total Pharmaceutical Contract Manufacturing Market: Percent Points Comparison with the US, Global, 2012 61 Total Pharmaceutical Contract Manufacturing Market: Percent Points Manufacturing Cost Comparison with the US, Global, 2012 62 Total Pharmaceutical Contract Manufacturing Market: Percent Points Labour Cost Comparison with the US, Global, 2012 62 Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Forecast by Region, Global, 2009–2017 63 Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast by Region, Global, 2009–2017 64 Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical Companies by Molecule Type, Global, 2012–2017 65
  • 28. 28NC04-52 Section Slide Number Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical Companies by Therapeutic Area, Global, 2012–2017 66 Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Big Pharmaceutical Companies by Molecule Type, Global, 2012–2017 67 Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Mid- sized Pharmaceutical Companies by Molecule Type, Global, 2012–2017 68 Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Activities Outsourced, Global, 2012 70 Total Pharmaceutical Contract Manufacturing Market: CAGRs of Segments Likely to Have Higher Levels of Outsourcing, Global, 2012–2019 70 Total Pharmaceutical Contract Manufacturing Market: Market Impact of Key Trends, Global, 2012 76 Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012 78 Total Pharmaceutical Contract Manufacturing Market: Percent Finished Dose Manufacturing Outsourced by Company Type, Global, 2012 82 Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs Companies Work With, Global, 2012 83 Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs Companies Work With by Company Type, Global, 2012 83 List of Exhibits (continued)
  • 29. 29NC04-52 List of Exhibits (continued) Section Slide Number Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by CMO Budget, Global, 2012 84 Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by Company Type, Global, 2012 85 Total Pharmaceutical Contract Manufacturing Market: Customer Utility Value of Various Factors Involved in the Selection of a CMO, Global, 2012 86 Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for CMO Selection, Global, 2012 87 Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for CMO Selection by Company Type, Global, 2012 88 Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service Areas, Global, 2012 91 Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service Areas, Global, 2017 91 Total Pharmaceutical Contract Manufacturing Market: Percent Outsourcing Budget Allocation Based on Product Revenue, Global, 2012 92 Total Pharmaceutical Contract Manufacturing Market: Outsourcing of Pharmaceutical Manufacturing Demand Forecast, Global, 2012–2017 93 Total Pharmaceutical Contract Manufacturing Market: Industry Capacity Utilization Forecast, Global, 2012–2017 94
  • 30. 30NC04-52 List of Exhibits (continued) Section Slide Number Total Pharmaceutical Contract Manufacturing Market: CMO Market Share, Global, 2012 97 Total Pharmaceutical Contract Manufacturing Market: CMO Market Share Analysis, Global, 2012 98 Total Pharmaceutical Contract Manufacturing Market: CMO Breakdown by Finished Dose Segments, Global, 2012 100 Solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global, 2012 131 Solid Dose Formulations Segment: Market Engineering Measurements, Global, 2012 132 Solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 133 Liquid and Semi-solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global, 2012 137 Liquid and Semi-solid Dose Formulations Segment: Market Engineering Measurements, Global, 2012 138 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 139 Injectable Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global, 2012 142 Injectable Dose Formulations Segment: Market Engineering Measurements, Global, 2012 143 Injectable Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 144
  • 31. 31NC04-52 List of Exhibits (continued) Section Slide Number Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, US, 2012 148 Pharmaceutical Contract Manufacturing Market: Revenue Forecast, US, 2009–2017 149 Solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 151 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 153 Injectable Dose Formulations Segment: Revenue Forecast, US, 2009–2017 156 Pharmaceutical Contract Manufacturing Market: Pricing Analysis, US, 2012 157 Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, US, 2012 159 Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Europe, 2012 161 Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Europe, 2009–2017 162 Solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 164 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 166 Injectable Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 168 Pharmaceutical Contract Manufacturing Market: Pricing Analysis, Europe, 2012 170 Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, Europe, 2012 172
  • 32. 32NC04-52 List of Exhibits (continued) Section Slide Number Solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 174 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009– 2017 176 Injectable Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 178 Solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 181 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 183 Injectable Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 185 Solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 188 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 190 Injectable Dose Formulations Segment: Revenue Forecast, France, 2009–2017 192 Solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 195 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 197 Injectable Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 199 Solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 202 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 204
  • 33. 33NC04-52 List of Exhibits (continued) Section Slide Number Injectable Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 206 Solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 209 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 211 Injectable Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 213 Solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 216 Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 218 Injectable Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 220 Total Pharmaceutical Contract Manufacturing Market: Important Market Growth Metrics, Global, 2012 271 Total Pharmaceutical Contract Manufacturing Market: Client-wise Revenue Contribution to CMOs, Global, 2012 274 Total Pharmaceutical Contract Manufacturing Market: VC Investment in Pharmaceutical/Biotech Companies and CMOs, Global, 2000–2011 280 Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent Protection, US, 2012–2017 282 Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent Protection, Europe, 2010–2017 284
  • 34. 34NC04-52 List of Exhibits (continued) Section Slide Number Decision Support Database: Total Healthcare Expenditure, Global, 2008-2018 291 Decision Support Database: Public Healthcare Expenditure, Global, 2008-2018 293 Decision Support Database: Private Healthcare Expenditure, Global, 2008-2018 295
  • 35. 35NC04-52 For more information Jennifer Carson Healthcare & Life Sciences (+1) 210.247.2450 jennifer.carson@frost.com